Basic Research “If you look at the cuts in the public sector, the science budget has been relatively lightly touched. This sends a signal at a very high level that science, the knowledge economy, and the smart training of people are very important for our economic recovery,” says Mark Ferguson, Director General,…
Life Sciences Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where Panion & BF will be in the next five years. Please provide us with a brief insight into the history…
Life Sciences James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech will be the leading industry in this new strategy and that less reliance on China will be necessary for an…
Life Sciences Wayne Samuels, partner at PwC Canada, discusses the most pressing issues in the country’s healthcare system and pharmaceutical industry, and outlines the changing dynamics in Canada’s pharma business model. What have been some of the key developments in life sciences during your tenure at PwC Canada so far? The most…
Bioscience The CEO of OBIO discusses Ontario’s challenges and opportunities in life sciences, highlighting some of the key initiatives that the organization is taking to help local companies bridge the gap between research and commercialization. What was your main objective in founding OBIO back in 2009? The main motivation for founding…
Brunel Warren Shapiro, manager of the North American division of Brunel’s life science sector, offers his insights into Canada’s immense human resources capabilities as well as Brunel’s footprint for contract labor in Canada’s life sciences industry in comparison to other worldwide regions. You have covered jurisdictions in Canada, US and Latin…
Ernst & Young LLP Mario Piccinin and Lara Iob of EY Canada discuss some of the key trends of the country’s biotech industry and the affiliate’s dedication to helping clients navigate the SR&ED tax credit process available in Canada. What do you see as the biggest challenges of life sciences clients in…
Agro-Food President of Biotalent Canada discusses the advantages of being wholly aligned with the government, why the BioTalent is a necessary link between talent and company, and what this means for the bio-economy of Canada. What was your initial mission two years ago upon arriving at Biotalent Canada, having previously worked…
Cardiology The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to bring CQDM to a more globally competitive level. You were appointed as CEO of CQDM about ten months ago. What…
Industrial Biotech Prior to joining Life Sciences Ontario (LSO), you served as CEO of GSK Canada for a number of years. What opportunities did you see in making the switch from an MNC to an association? Having been in the pharmaceutical business for my entire career in Canada, I have always been…
Hsinchu Science Park The Director General of one of the world’s most successful science parks discusses the history of the park, the reasons behind its incredible success, the unique set-up of the park which allows its administation board to act as a one-stop shop for tenants in terms of regulation and approvals, and…
ProMetic Life Sciences Inc. Mr. Pierre Laurin is a senior executive with 28 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic’s platform technology since 1989, Mr. Laurin founded ProMetic Life Sciences Inc. in 1994. As Chairman until March, 2011 and President and CEO of the Corporation since…
See our Cookie Privacy Policy Here
